Bibliometric analysis of natural products and intestinal barrier research (2004–2025)
A bibliometric mapping of 1,679 publications describes the growth of the field but does not demonstrate clinical efficacy of any natural product on the intestinal barrier.
| Population | Global scientific literature on natural products and intestinal barrier (2004–2025) |
|---|---|
| Intervention | Bibliometric analysis of 1,679 records from Web of Science and PubMed |
| Comparator | Not applicable (descriptive literature study) |
| Outcome | Scientific output volume and growth; National leadership in output and citations; Dominant themes by keyword co-occurrence; Central mechanistic hub (NF-κB); Most studied natural product category (polyphenols); International collaboration among countries/institutions; Emerging frontiers and burst topics (microbiota, TJs, mucosal repair) |
Summary of findings
| Outcome | Effect | 95% CI | Certainty | Clinical relevance | Notes |
|---|---|---|---|---|---|
| Scientific output volume and growth | 1679 records, 63 countries, 2004-2025; in the effect size applicable | — | Low | — | 1679 studies |
| National leadership in output and citations | China: 682 publications, 15987 citations; in the comparative effect size | — | Low | — | |
| Dominant themes by keyword co-occurrence | Descriptive; in the statistical effect size reported | — | Very low | — | 1679 studies |
| Central mechanistic hub (NF-κB) | Keyword frequency analysis only; in the quantitative effect size | — | Very low | — | |
| Most studied natural product category (polyphenols) | Descriptive bibliometric ranking; in the efficacy data | — | Very low | — | |
| International collaboration among countries/institutions | 63 countries identified; collaboration network mapped descriptively; in the effect size | — | Very low | — | |
| Emerging frontiers and burst topics (microbiota, TJs, mucosal repair) | Burst detection descriptive; in the quantitative effect size | — | Very low | — |
Context
Intestinal barrier integrity is mechanistically linked to inflammatory, metabolic, and immunological diseases. Natural products are studied as modulators of tight junctions, microbiota, and inflammation. Publication volume grew substantially between 2004 and 2025, but the knowledge structure and emerging frontiers remained poorly characterized.
What the study showed
1,679 records from 63 countries were identified. China leads in output (682 publications) and citations (15,987 citations). Central thematic pillars are gut microbiota, inflammation, and oxidative stress; NF-κB is the most cited mechanistic hub. Polyphenols are the most studied category and resveratrol is the most recurrent cross-mechanism compound. No clinical efficacy data, effect sizes, or patient outcomes are reported.
How it was done
Observational bibliometric study. Search in Web of Science Core Collection and PubMed (01/01/2004 to 11/06/2025). Tools: CiteSpace, VOSviewer, R (Biblioshiny), SCImago Graphica. Keyword co-occurrence, co-citation, output by country/institution/author, and thematic burst detection. No primary data extraction, no efficacy synthesis.
Effect magnitude
No calculable effect size: the study does not synthesize experimental or clinical data. The only quantitative indicators are publication volume and citation counts by country.
Risk of bias
No risk-of-bias tool (RoB 2, ROBINS-I, AMSTAR-2) is applicable or used, as the design is descriptive bibliometric. Search is limited to Web of Science and PubMed, excluding Embase, Scopus, and grey literature, potentially under-representing non-English-language publications. Keyword co-occurrence reflects editorial frequency, not evidence hierarchy; Chinese predominance may reflect indexing bias and self-citation.
What this study does NOT prove
This study does not prove that any natural product protects the intestinal barrier in humans. It establishes no causality, quantifies no efficacy, allows no comparison between interventions, and is not generalizable to clinical populations.
In clinical practice
This study generates no clinical recommendations. Clinicians must not interpret publication volume or keyword frequency as evidence of clinical efficacy of polyphenols or resveratrol. The field's acknowledged absence of robust RCTs and meta-analyses means no natural product has sufficient clinical validation for therapeutic indication targeting intestinal barrier function.
Limitations
No risk-of-bias tool (RoB 2, ROBINS-I, AMSTAR-2) is applicable or used, as the design is descriptive bibliometric. Search is limited to Web of Science and PubMed, excluding Embase, Scopus, and grey literature, potentially under-representing non-English-language publications. Keyword co-occurrence reflects editorial frequency, not evidence hierarchy; Chinese predominance may reflect indexing bias and self-citation.
What is still missing
Multicenter RCTs and meta-analyses with validated clinical outcomes (measured intestinal permeability, inflammatory markers, clinical events) are needed. Broader international collaboration and standardization of experimental models are prerequisites for clinical translation.
Technical appendix
Version history
- 1.0 · 2026-09-17 — Auto-generated under Evidence Standard v1.0